A new Virginia law governing collaborations between nurse practitioners and doctors leaves unresolved key legal issues in team-based care, including those pertaining to medical malpractice and liability and anticompetitive practices.
Deciding whether to recommend Avastin or Lucentis raises ethical issues. Should the public health consequences of using a far more expensive drug trump what the doctor thinks is best for the individual patient?